vaccin
develop
tradit
lengthi
pursuit
protract
develop
time
high
liabil
risk
vaccin
given
healthi
peopl
low
rate
return
curb
enthusiasm
big
compani
vaccin
r
even
worldwid
vaccin
market
grow
billion
ref
predict
merril
lynch
new
york
repres
fraction
revenu
drug
avail
fund
us
govern
biodefens
program
make
biotech
compani
take
closer
look
result
slew
novel
treatment
technolog
speed
develop
new
vaccin
candid
tabl
simplest
form
vaccin
made
kill
pathogen
inject
directli
person
spur
product
antibodi
expos
antigen
pathogen
surfac
unfortun
microb
surfaceexpos
antigen
often
ineffect
elicit
protect
immun
refin
techniqu
vaccinologist
purifi
protein
subunit
target
inject
subunit
laboratori
anim
even
human
volunt
tri
identifi
best
antigen
applic
genet
engin
also
allow
first
recombin
subunit
vaccin
produc
circumv
problem
contamin
blood
compon
product
result
mix
mani
pathogen
antigen
protein
may
express
low
level
complic
identif
purif
purif
procedur
may
destroy
antigen
structur
anoth
tradit
techniqu
first
pioneer
albert
sabin
pathogen
repeatedli
pass
differ
tissu
cultur
anim
host
virul
bred
though
sabin
polio
vaccin
cornerston
world
health
organ
geneva
campaign
erad
diseas
attenu
vaccin
diseas
difficult
develop
deliv
one
common
problem
live
vaccin
sometim
mutat
back
virul
form
caus
diseas
suppos
prevent
advent
whole
genom
sequenc
howev
led
vaccin
research
pursu
revers
vaccinolog
instead
start
whole
organ
approach
begin
genom
sequenc
pathogen
research
compar
sequenc
sequenc
known
antigen
toxin
identifi
like
vaccin
antigen
use
recombin
express
system
express
candid
gene
seri
screen
anim
test
identifi
immunogen
product
form
basi
experiment
vaccin
chiron
vaccin
oxford
uk
coin
term
revers
vaccinolog
alreadi
demonstr
method
potenti
compani
conjug
subunit
vaccin
target
type
c
meningococc
diseas
caus
neisseria
meningitidi
mening
c
almost
erad
uk
vaccin
say
rob
budg
spokesman
chiron
add
product
call
menjug
phase
clinic
trial
unit
state
chiron
also
use
revers
vaccinolog
develop
seri
product
includ
mening
type
b
vaccin
tailormad
combat
unusu
strain
bacterium
plagu
new
zealand
past
year
revers
vaccinolog
requir
whole
genom
sequenc
inform
shortag
sinc
viral
genom
small
nearli
medic
import
one
alreadi
fulli
sequenc
complex
genom
rapidli
pile
public
databas
count
sequenc
project
support
us
nation
institut
allergi
infecti
diseas
bethesda
md
usa
four
dozen
major
bacteri
protozoan
pathogen
least
one
arthropod
diseas
vector
genom
complet
sequenc
dozen
addit
sequenc
project
underway
tabl
besid
sequenc
gaze
complet
genom
also
enabl
transcript
profil
help
identifi
gene
product
associ
virul
invas
bacteria
protozoan
often
express
virul
factor
certain
cell
type
particular
environment
condit
comparison
express
profil
could
highlight
promis
vaccin
immunotherapi
target
approach
still
quit
new
transcript
profil
chip
bacteri
pathogen
fund
biodefens
spur
new
vaccin
antiinfect
program
sever
biotech
compani
vaccin
product
enter
centuri
technician
make
vaccin
mammalian
cell
cultur
imag
courtest
chiron
emoryvil
ca
usa
becom
avail
expect
genom
sequenc
effort
progress
compani
take
technolog
alreadi
appli
drug
develop
adapt
vaccin
antiinfect
program
diversa
san
diego
ca
usa
exampl
best
known
direct
evolut
techniqu
entail
gener
wide
rang
variat
protein
amino
acid
sequenc
select
variant
desir
characterist
enjoy
major
success
enzym
heatstabl
dna
polymeras
pcr
novel
nitrilas
chiral
chemic
synthesi
diversa
look
immunoglobulin
alreadi
start
work
number
antibodi
shown
actual
rebuild
antibodi
like
mosaic
antibodi
far
superior
say
gari
woodnutt
senior
vice
presid
pharmaceut
research
develop
diversa
fig
immun
system
natur
carri
similar
select
process
antibodi
woodnutt
argu
move
rearrang
test
tube
make
process
easier
direct
monitor
potenti
shorten
develop
time
compani
also
borrow
page
darwin
develop
new
vaccin
maxygen
redwood
citi
ca
usa
exampl
use
direct
evolut
strategi
systemat
select
improv
antigen
therapeut
protein
vaccin
market
compani
two
lead
product
therapeut
colon
cancer
vaccin
vaccin
dengu
fever
design
protect
four
serotyp
viru
product
preclin
develop
produc
highaffin
antibodi
good
first
step
ultim
vaccin
must
manufactur
larg
quantiti
deliv
effici
patient
although
compani
focus
product
system
see
box
other
tri
develop
generalpurpos
deliveri
system
adapt
varieti
immun
one
approach
harken
back
oldest
vaccin
system
edward
jenner
use
vaccinia
viru
deliv
crossprotect
antigen
smallpox
better
understand
biolog
behind
vaccin
research
modifi
vaccinia
viru
deliv
antigen
pathogen
rabi
viru
larg
dna
viru
vaccinia
easili
engin
carri
addit
antigen
gene
take
advantag
approach
incel
san
antonio
tx
usa
develop
modifi
vaccinia
ankara
viru
associ
mani
advers
event
older
strain
creat
smallpox
vaccin
administ
oral
potenti
elicit
strong
mucos
system
immun
plenti
room
virus
market
though
sinc
patient
immun
one
vector
may
develop
antibodi
vector
make
subsequ
vaccin
less
effect
alphavax
research
triangl
park
nc
usa
use
disabl
venezuelan
equin
enceph
viru
deliveri
express
system
like
vaccinia
compani
recombin
viru
manipul
rel
easili
cultur
abl
elicit
robust
immun
respons
virtual
target
score
gene
differ
engin
system
alphavax
differ
academ
institut
us
armi
research
facil
fort
detrick
flexibl
adapt
system
say
peter
young
ceo
alphavax
besid
shorten
preclin
develop
process
use
similar
system
mani
vaccin
might
help
reduc
inher
risk
vaccin
busi
cours
build
increasingli
robust
regulatori
clinic
foundat
technolog
gener
think
increasingli
facilit
subsequ
develop
review
addit
product
applic
say
young
anoth
advantag
use
viru
express
antigen
host
cell
rather
inject
antigen
cellular
express
often
produc
cytotox
immun
respons
well
antibodymedi
respons
viral
infect
especi
cytotox
respons
often
primari
mean
clear
pathogen
respect
viral
vector
offer
mani
benefit
live
attenu
viral
vaccin
without
potenti
side
effect
steven
projan
assist
vicepresid
discoveri
research
wyethayerst
research
philadelphia
pa
usa
enthusiast
approach
nonrepl
viral
vector
give
round
gene
express
without
potenti
outbreak
viral
infectioni
think
go
perhap
import
technolog
vaccin
develop
futur
alphavax
lead
hiv
vaccin
enter
clinic
trial
last
year
biodefens
also
major
focu
compani
receiv
fund
develop
vaccin
botulinum
toxin
marburg
viru
pathogen
inde
alphavax
among
small
cadr
biotech
grant
money
ventur
capit
fund
oper
anoth
compani
pursu
vectorbas
approach
case
use
bacteria
avant
immunotherapeut
needham
usa
avant
use
nonpathogen
strain
salmonella
enterica
serovar
typhi
typhimurium
vibrio
cholera
surviv
well
human
digest
tract
express
foreign
antigen
provid
immun
pathogen
interest
compani
conduct
clinic
trial
vaccin
rotaviru
cholera
typhoid
fever
anthrax
besid
provid
generalpurpos
vaccin
develop
system
mani
vectorbas
approach
could
also
eas
vaccin
deliveri
sinc
enter
bacteria
surviv
digest
tract
exampl
avant
work
formul
vaccin
oral
deliveri
plu
abil
load
multipl
antigen
singl
dose
vaccin
major
sell
point
product
design
mass
immun
program
addit
improv
develop
deliveri
new
technolog
may
help
address
longstand
difficulti
vaccin
manufactur
everi
drug
vaccin
face
product
challeng
problem
perhap
sever
influenza
vaccin
year
vaccin
base
educ
guess
made
public
health
offici
tri
predict
februari
march
strain
viru
preval
next
winter
flu
outbreak
compani
expect
ten
million
dose
vaccin
made
viral
cultur
grown
insid
chicken
egg
readi
septemb
influenza
vaccin
product
plant
around
world
truckload
egg
begin
arriv
earli
spring
actual
yield
vaccin
dose
per
egg
close
guard
trade
secret
chiron
budg
disclos
everi
day
got
come
facil
ten
hundr
thousand
egg
addit
mundan
concern
ensur
chicken
farmer
ramp
egg
product
earli
enough
meet
enorm
demand
flu
vaccin
maker
must
also
isol
viru
strain
right
serotyp
virul
egg
egg
virul
could
particular
problem
year
sinc
public
health
offici
debat
whether
includ
highli
pathogen
hemagglutinin
avian
influenza
strain
next
year
shot
viru
deadli
chicken
would
like
grow
poorli
egg
though
peopl
southeast
asia
infect
bird
flu
current
outbreak
via
direct
birdtohuman
contact
increas
fear
could
cross
speci
instead
tri
reverseengin
pathogen
see
main
text
compani
updat
classic
strategi
tool
biotechnolog
one
old
techniqu
manufactur
immunotherapi
toxin
inject
animaloften
horsewith
target
agent
use
anim
serum
directli
antitoxin
approach
effect
crude
util
often
limit
massiv
immun
respons
patient
develop
entir
foreign
antibodi
use
transgen
clone
technolog
hematech
sioux
fall
sd
usa
tri
bring
barnyard
strategi
biodefens
product
system
cow
contain
microchromosom
full
sequenc
human
heavyand
lightchain
antibodi
gene
say
jame
robl
presid
hematech
engin
cattl
rearrang
human
antibodi
gene
endogen
antibodi
loci
challeng
antigen
cow
respond
bovin
fulli
human
antibodi
type
antibodi
undergo
immunoglobulin
classswitch
affin
matur
set
biodefens
grant
hematech
current
use
cow
manufactur
antisera
five
serotyp
botulinum
toxin
well
antigen
anthrax
bacteria
vaccinia
virus
none
product
would
prophylact
vaccin
could
supplement
rapid
respons
deliber
accident
releas
pathogen
toxin
robl
envis
develop
similar
therapi
respond
emerg
pathogen
like
sar
cow
may
soon
feather
compani
tranxenogen
shrewsburi
usa
avigen
athen
ga
usa
use
egg
transgen
chicken
produc
recombin
protein
includ
monoclon
antibodi
viral
antigen
sinc
flu
vaccin
maker
alreadi
establish
highvolum
product
system
base
egg
system
easi
scale
meanwhil
origen
therapeut
burlingam
ca
usa
use
approach
like
hematech
chicken
use
bird
gener
human
polyclon
antibodi
barrier
start
human
pandem
humantohuman
spread
chiron
work
cellbas
manufactur
system
bypass
mani
difficulti
expect
take
flu
vaccin
manufactur
cell
cultur
phase
clinic
trial
year
think
advantag
term
time
get
vaccin
market
also
term
product
addit
flexibl
say
budg
new
system
probabl
shorten
product
cycl
week
even
could
addit
benefit
public
health
public
health
offici
tight
deadlin
guess
wrong
omit
one
viral
strain
vaccin
predomin
mani
region
flu
season
allow
littl
time
determin
vaccin
makeup
might
reduc
error
altern
approach
would
nt
requir
switch
product
method
involv
process
call
revers
genet
develop
gaithersburg
marylandbas
medimmun
vaccin
formerli
aviron
acquir
medimmun
technolog
reduc
pathogen
viru
creat
mutant
viral
hemagglutinin
gene
research
collabor
sever
intern
group
develop
prototyp
vaccin
avian
flu
strain
use
techniqu
arrang
medimmun
hold
patent
accord
medimmun
spokesperson
jami
lacey
compani
inform
make
intellectu
properti
avail
event
pandem
everyon
vaccin
bandwagon
focus
standalon
treatment
inde
effect
strategi
small
compani
may
find
way
boost
effect
product
elusi
pine
brook
nj
usa
primari
technolog
involv
coval
link
antibodi
complement
receptor
antibodi
target
toxin
pathogen
inject
bloodstream
twohead
molecul
tag
target
destruct
liver
effect
clear
foreign
agent
system
fig
look
vaccinia
mitig
complic
smallpox
look
flavivirus
like
dengu
japanes
enceph
west
nile
viru
well
staphylococc
bacteri
infect
say
linda
nardon
vice
presid
clinic
regulatori
affair
elusi
though
link
antibodi
compani
main
thrust
elusi
lead
product
actual
highaffin
monoclon
antibodi
mab
protect
antigen
bacillu
anthraci
far
shown
promis
result
mice
rabbit
expos
anthrax
spore
compani
includ
human
genom
scienc
rockvil
md
usa
avanir
pharmaceut
san
diego
ca
usa
also
work
anthrax
mab
clinic
trial
product
may
await
passag
bioshield
mammoth
biodefens
fund
initi
propos
year
ago
bush
administr
see
box
unlik
tradit
vaccin
immunotherapi
like
elusi
induc
robust
host
immun
respons
instead
reduc
concentr
pathogen
toxin
bloodstream
may
cure
diseas
way
may
give
person
real
shot
take
care
infect
know
aid
viral
load
crucial
say
nardon
add
antibodybas
system
anyth
bloodborn
believ
taken
circul
practic
antiinfect
immunotherapi
probabl
combin
treatment
obviou
area
partnership
vaccin
manufactur
though
also
least
glamor
almost
vaccin
deliv
along
chemic
compound
increas
immunogen
research
explor
potenti
improv
adjuv
inde
genuin
new
adjuv
approv
us
food
drug
administr
fda
rockvil
md
usa
least
year
capit
serendipit
find
made
antisens
research
coley
pharmaceut
wellesley
usa
hope
fill
void
knowledg
furthest
along
adjuv
say
robert
bratzler
presid
ceo
coley
compani
main
product
cpgcontain
oligonucleotid
bind
complement
tolllik
receptor
first
compani
tri
develop
antisens
oligonucleotid
therapi
discov
cpgcontain
sequenc
provid
strong
nonspecif
boost
immun
system
enorm
disappoint
nascent
antisens
industri
hope
highli
specif
genesilenc
respons
coley
hope
make
lemon
lemonad
year
think
cpg
standard
adjuv
use
vaccin
mani
advantag
say
arthur
krieg
coley
cso
oligonucleotid
seem
provid
stronger
immunolog
boost
compet
product
like
aluminum
hydroxid
alum
main
adjuv
use
human
vaccin
nearli
year
current
fda
regimen
anthrax
vaccin
six
dose
period
month
say
krieg
cpg
adjuv
get
protect
respons
within
one
two
dose
vast
major
peopl
interestingli
cpg
adjuv
also
provid
shortterm
protect
wide
rang
pathogen
suggest
could
use
immedi
aftermath
diseas
outbreak
even
specif
pathogen
known
coley
receiv
biodefens
grant
studi
aspect
compound
compani
also
collabor
sever
major
vaccin
manufactur
emerg
new
approach
promis
reinvigor
vaccin
research
may
sever
year
shorten
lag
discoveri
new
diseas
product
effect
vaccin
meanwhil
old
way
sometim
work
surprisingli
well
research
given
suffici
motiv
sever
acut
respiratori
syndrom
sar
exampl
caus
coronaviru
famili
virus
long
familiar
veterinari
research
one
compani
sinovac
biotech
beij
china
alreadi
start
clinic
trial
promis
sar
vaccin
sever
other
gotten
posit
preclin
result
sinovac
product
base
one
oldest
simplest
vaccin
strategi
contain
whole
kill
viru
even
new
vaccin
work
market
still
concern
think
probabl
share
rest
industri
view
sar
hard
predict
stage
kind
commerci
opportun
go
say
peter
young
ceo
alphavax
research
triangl
park
nc
usa
new
batch
money
promis
biodefens
suppos
quell
concern
although
compani
vaccin
field
remain
wari
depend
govern
dole
gener
optimist
ever
sinc
richard
nixon
declar
war
cancer
militari
rhetor
stapl
discuss
biomed
research
fund
advent
war
bioterror
perhap
vaccin
histor
one
medicin
power
weapon
final
get
longawait
upgrad
